Short-course low-dose steroids to calm inflammation in severe pancreatitis
Corticosteroids to Reduce Inflammation in Severe Pancreatitis (CRISP)
A short course of low-dose corticosteroids will be given to people with severe acute pancreatitis to try to reduce inflammation and lower the risk of organ and breathing failure.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11238561 on NIH RePORTER |
What this research studies
If you join, you would receive a brief course of physiologic-dose corticosteroids early during your hospital stay for severe acute pancreatitis. The care team will closely monitor your breathing, organ function, complications, and recovery while comparing these outcomes to patients who receive usual care. Treatment and follow-up would occur while you are hospitalized and during active follow-up after discharge. The goal is to see whether an early, short steroid course can prevent progression to respiratory failure or multi-organ injury.
Who could benefit from this research
Good fit: Adults hospitalized with acute severe non-autoimmune pancreatitis early in their illness and who can safely receive corticosteroids are the intended candidates.
Not a fit: People with mild pancreatitis, autoimmune pancreatitis, active uncontrolled infections, or medical contraindications to steroids are unlikely to benefit from this treatment.
Why it matters
Potential benefit: If successful, this approach could reduce respiratory failure, organ injury, and deaths from severe pancreatitis and shorten hospital stays.
How similar studies have performed: Steroids have shown benefit for other inflammation-driven conditions like sepsis, ARDS, and COVID-19, but evidence specifically for pancreatitis is limited to small pilot trials.
Where this research is happening
Boston, United States
- Beth Israel Deaconess Medical Center — Boston, United States (Active)
Researchers
- Principal investigator: Donnino, Michael William — Beth Israel Deaconess Medical Center
- Study coordinator: Donnino, Michael William
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.